Literature DB >> 29949089

Invasive Candida auris infections in Kuwait hospitals: epidemiology, antifungal treatment and outcome.

Ziauddin Khan1,2, Suhail Ahmad3,4, Khalifa Benwan5, Prashant Purohit6, Inaam Al-Obaid6, Ritu Bafna6, Maha Emara6, Eiman Mokaddas3,7, Aneesa Ahmed Abdullah7, Khaled Al-Obaid4, Leena Joseph3.   

Abstract

PURPOSE: Candida auris is a recently recognized yeast pathogen, which has attracted worldwide attention due to its multidrug-resistant nature and associated high mortality rates. Its persistence in hospital environment and propensity of nosocomial transmission underscores the need of continuous monitoring to prevent outbreaks. Since the first case of C. auris candidemia in May, 2014, we have identified 17 additional invasive cases, which are described here.
METHODS: Identity of 17 isolates originating from proven or possible cases of invasive C. auris infection and identified as Candida haemulonii by Vitek 2 yeast identification system was confirmed by PCR-sequencing of rDNA. Information about risk factors, treatment and outcomes were retrospectively retrieved from case files. Antifungal susceptibility testing was performed by Etest.
RESULTS: Thirteen cases of candidemia and 4 cases of other invasive infections were detected in 6 hospitals across Kuwait. Major risk factors included adult patients with cancer, diabetes, gastrointestinal/liver diseases and extended (> 25 days) hospital stay. All isolates were resistant to fluconazole. Additionally, 5 and 4 isolates were also resistant to voriconazole and amphotericin B, respectively. Despite antifungal treatment, 9 of 15 patients died. Most patients (n = 12) were hospitalized in 2 hospitals that are in close proximity, whereas 5 other patients were from 3 hospitals that are situated > 10 km apart.
CONCLUSIONS: Occurrence of successive cases of invasive C. auris infections with resulting mortality in nine patients suggests persistence of this multidrug-resistant yeast in major hospitals in Kuwait. Early detection by continuous surveillance and enforcement of infection control measures are recommended.

Entities:  

Keywords:  Antifungal susceptibility; Candida auris; Epidemiology; Invasive infections; Kuwait

Mesh:

Substances:

Year:  2018        PMID: 29949089     DOI: 10.1007/s15010-018-1164-y

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  39 in total

1.  Isolation of Candida auris from 9 patients in Central America: Importance of accurate diagnosis and susceptibility testing.

Authors:  Ana Belen Araúz; Diego H Caceres; Erika Santiago; Paige Armstrong; Susan Arosemena; Carolina Ramos; Andres Espinosa-Bode; Jovanna Borace; Lizbeth Hayer; Israel Cedeño; Brendan R Jackson; Nestor Sosa; Elizabeth L Berkow; Shawn R Lockhart; Amalia Rodriguez-French; Tom Chiller
Journal:  Mycoses       Date:  2017-10-16       Impact factor: 4.377

2.  Candida auris candidaemia in Indian ICUs: analysis of risk factors.

Authors:  Shivaprakash M Rudramurthy; Arunaloke Chakrabarti; Raees A Paul; Prashant Sood; Harsimran Kaur; Malini R Capoor; Anupma J Kindo; Rungmei S K Marak; Anita Arora; Raman Sardana; Shukla Das; Deepinder Chhina; Atul Patel; Immaculata Xess; Bansidhar Tarai; Pankaj Singh; Anup Ghosh
Journal:  J Antimicrob Chemother       Date:  2017-06-01       Impact factor: 5.790

3.  Incidence, characteristics and outcome of ICU-acquired candidemia in India.

Authors:  Arunaloke Chakrabarti; Prashant Sood; Shivaprakash M Rudramurthy; Sharon Chen; Harsimran Kaur; Malini Capoor; Deepinder Chhina; Ratna Rao; Vandana Kalwaje Eshwara; Immaculata Xess; Anupama J Kindo; P Umabala; Jayanthi Savio; Atul Patel; Ujjwayini Ray; Sangeetha Mohan; Ranganathan Iyer; Jagdish Chander; Anita Arora; Raman Sardana; Indranil Roy; B Appalaraju; Ajanta Sharma; Anjali Shetty; Neelam Khanna; Rungmei Marak; Sanjay Biswas; Shukla Das; B N Harish; Sangeeta Joshi; Deepak Mendiratta
Journal:  Intensive Care Med       Date:  2014-12-16       Impact factor: 17.440

4.  Antifungal susceptibility of clinical Candida parapsilosis isolates in Kuwait.

Authors:  Mohammad Asadzadeh; Noura A Al-Sweih; Suhail Ahmad; Zia U Khan
Journal:  Mycoses       Date:  2008-07       Impact factor: 4.377

5.  Evidence of genotypic diversity among Candida auris isolates by multilocus sequence typing, matrix-assisted laser desorption ionization time-of-flight mass spectrometry and amplified fragment length polymorphism.

Authors:  A Prakash; C Sharma; A Singh; P Kumar Singh; A Kumar; F Hagen; N P Govender; A L Colombo; J F Meis; A Chowdhary
Journal:  Clin Microbiol Infect       Date:  2015-11-05       Impact factor: 8.067

6.  Candida auris sp. nov., a novel ascomycetous yeast isolated from the external ear canal of an inpatient in a Japanese hospital.

Authors:  Kazuo Satoh; Koichi Makimura; Yayoi Hasumi; Yayoi Nishiyama; Katsuhisa Uchida; Hideyo Yamaguchi
Journal:  Microbiol Immunol       Date:  2009-01       Impact factor: 1.955

7.  First hospital outbreak of the globally emerging Candida auris in a European hospital.

Authors:  Silke Schelenz; Ferry Hagen; Johanna L Rhodes; Alireza Abdolrasouli; Anuradha Chowdhary; Anne Hall; Lisa Ryan; Joanne Shackleton; Richard Trimlett; Jacques F Meis; Darius Armstrong-James; Matthew C Fisher
Journal:  Antimicrob Resist Infect Control       Date:  2016-10-19       Impact factor: 4.887

8.  The Emerging Pathogen Candida auris: Growth Phenotype, Virulence Factors, Activity of Antifungals, and Effect of SCY-078, a Novel Glucan Synthesis Inhibitor, on Growth Morphology and Biofilm Formation.

Authors:  Emily Larkin; Christopher Hager; Jyotsna Chandra; Pranab K Mukherjee; Mauricio Retuerto; Iman Salem; Lisa Long; Nancy Isham; Laura Kovanda; Katyna Borroto-Esoda; Steve Wring; David Angulo; Mahmoud Ghannoum
Journal:  Antimicrob Agents Chemother       Date:  2017-04-24       Impact factor: 5.191

9.  Candida auris: epidemiological situation, laboratory capacity and preparedness in European Union and European Economic Area countries, 2013 to 2017.

Authors:  Anke Kohlenberg; Marc J Struelens; Dominique L Monnet; Diamantis Plachouras
Journal:  Euro Surveill       Date:  2018-03

10.  Increasing prevalence, molecular characterization and antifungal drug susceptibility of serial Candida auris isolates in Kuwait.

Authors:  Ziauddin Khan; Suhail Ahmad; Noura Al-Sweih; Leena Joseph; Wadha Alfouzan; Mohammad Asadzadeh
Journal:  PLoS One       Date:  2018-04-09       Impact factor: 3.240

View more
  19 in total

Review 1.  Candida auris: a fungus with identity crisis.

Authors:  Taissa Vila; Ahmed S Sultan; Daniel Montelongo-Jauregui; Mary Ann Jabra-Rizk
Journal:  Pathog Dis       Date:  2020-06-01       Impact factor: 3.166

2.  In Vitro Activity of Ibrexafungerp (SCY-078) against Candida auris Isolates as Determined by EUCAST Methodology and Comparison with Activity against C. albicans and C. glabrata and with the Activities of Six Comparator Agents.

Authors:  Maiken Cavling Arendrup; Karin Meinike Jørgensen; Rasmus Krøger Hare; Anuradha Chowdhary
Journal:  Antimicrob Agents Chemother       Date:  2020-02-21       Impact factor: 5.191

Review 3.  Antifungal Resistance: a Concerning Trend for the Present and Future.

Authors:  Joshua A Hendrickson; Chenlin Hu; Samuel L Aitken; Nicholas Beyda
Journal:  Curr Infect Dis Rep       Date:  2019-11-16       Impact factor: 3.725

4.  Transcriptional Response of Candida auris to the Mrr1 Inducers Methylglyoxal and Benomyl.

Authors:  Amy R Biermann; Deborah A Hogan
Journal:  mSphere       Date:  2022-04-27       Impact factor: 5.029

Review 5.  Update on invasive fungal infections in the Middle Eastern and North African region.

Authors:  Marwan Osman; Aisha Al Bikai; Rayane Rafei; Hassan Mallat; Fouad Dabboussi; Monzer Hamze
Journal:  Braz J Microbiol       Date:  2020-07-05       Impact factor: 2.476

Review 6.  Identification of Drug Resistant Candida auris.

Authors:  Milena Kordalewska; David S Perlin
Journal:  Front Microbiol       Date:  2019-08-20       Impact factor: 5.640

Review 7.  New and emerging infectious diseases (Ebola, Middle Eastern respiratory syndrome coronavirus, carbapenem-resistant Enterobacteriaceae, Candida auris): Focus on environmental survival and germicide susceptibility.

Authors:  David J Weber; Emily E Sickbert-Bennett; Hajime Kanamori; William A Rutala
Journal:  Am J Infect Control       Date:  2019-06       Impact factor: 2.918

8.  Antifungal drug susceptibility, molecular basis of resistance to echinocandins and molecular epidemiology of fluconazole resistance among clinical Candida glabrata isolates in Kuwait.

Authors:  Zahraa F Al-Baqsami; Suhail Ahmad; Ziauddin Khan
Journal:  Sci Rep       Date:  2020-04-10       Impact factor: 4.379

Review 9.  Nine Things Genomics Can Tell Us About Candida auris.

Authors:  Aleksandra D Chybowska; Delma S Childers; Rhys A Farrer
Journal:  Front Genet       Date:  2020-04-15       Impact factor: 4.599

10.  Murine model of colonization with fungal pathogen Candida auris to explore skin tropism, host risk factors and therapeutic strategies.

Authors:  Xin Huang; Charlotte Hurabielle; Rebecca A Drummond; Nicolas Bouladoux; Jigar V Desai; Choon K Sim; Yasmine Belkaid; Michail S Lionakis; Julia A Segre
Journal:  Cell Host Microbe       Date:  2020-12-31       Impact factor: 21.023

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.